Form 4: Nuvalent Director Sapna Srivastava Granted Equity Awards Valued at Over $300,000

Nuvalent, Inc. Director Sapna Srivastava was granted 2,647 restricted stock units and 4,147 stock options, aligning her interests with shareholders.

Summary

• Nuvalent, Inc. Director Sapna Srivastava was granted 2,647 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 18, 2025, with a grant price of $0.00.
• Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock.
• These RSUs will vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• Ms. Srivastava also received 4,147 stock options (right to buy) on June 18, 2025, with an exercise price of $75.53 per share.
• The stock options have an expiration date of June 18, 2035.
• The shares underlying these options will vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• Following these transactions, Ms. Srivastava beneficially owns 5,146 shares of Class A Common Stock and 4,147 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It is a routine transaction, so not highly impactful on its own.

Positives

• The grant of equity awards to Director Sapna Srivastava aligns her financial interests with those of Nuvalent, Inc.'s shareholders, promoting long-term value creation.
• The vesting schedule, tied to continued service, incentivizes the director's ongoing commitment to the company.

Future Outlook

The granted Restricted Stock Units and stock options are subject to future vesting, which will occur on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent upon the director's continued service to the company.

Industry Context

This filing represents a routine equity compensation grant to a director, a common practice across publicly traded companies in the biotechnology and pharmaceutical sectors to attract and retain experienced board members and align their interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The transaction involves the issuance of equity awards (Restricted Stock Units and stock options) by Nuvalent, Inc. to Sapna Srivastava, a director of the company. This constitutes a related party transaction as it is between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• Vesting of 2,647 Restricted Stock Units on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Vesting of 4,147 stock options on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Potential exercise of stock options by June 18, 2035, upon vesting.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership